Cancer Family
Salivary Gland Neoplasm
CI-CAN-00000343Explore in graph →
Loading cancer entity…
Cancer Family
CI-CAN-00000343Explore in graph →
Variants & evidence
21 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AR AR-V71 | ||||||||
| Abiraterone Acetate | Malignant Salivary Gland NeoplasmALIAS | Predictive | C | Supports Resistance | 2 | submitted | EID6954Case Report of a Patient with metastatic salivary gland cancer with androgen receptor overexpression under treatment with abiraterone. The patient experienced stable disease for 6 months. Analysis of … (full text at CIViC) PMID 29897400 · Cappelletti et al., 2018 · Open in CIViC | civic |
| AR OVEREXPRESSION1 | ||||||||
| Bicalutamide + LeuprolideCombination | Malignant Salivary Gland NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID6953In this single institution, open-label, single arm, phase II Trial, salivary gland carcinomas, staining positive for androgen receptor expression on IHC (minimum of 1% tumor cells), were treated with … (full text at CIViC) PMID 29211833 · Fushimi et al., 2018 · Open in CIViC | civic |
| BRAF Kinase Domain Duplication1 | ||||||||
| Regorafenib | Acinar Cell CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID12470A 30 year old women with advanced acinic cell tumor of the right parotid gland had her disease progressed after initial systemic chemotherapy, followed by empirical erlotinib hydrochloride therapy. Pr… (full text at CIViC) PMID 26562024 · Klempner et al., 2016 · Open in CIViC | civic |
| ERBB2 Amplification2 | ||||||||
| Pertuzumab + TrastuzumabCombination | Salivary Gland Carcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID5984The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC | civic |
| Trastuzumab Emtansine | Malignant Salivary Gland NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7856In NCI-MATCH, patients with advanced solid tumors other than breast and gastro-esophageal tumors harboring ERBB2 amplification were treated with ad-trastuzumab emtansine (T-DM1). ERBB2 amplification w… (full text at CIViC) PMID 31504139 · Jhaveri et al., 2019 · Open in CIViC | civic |
| ERBB2 Overexpression3 | ||||||||
| Docetaxel + TrastuzumabCombination | Malignant Salivary Gland NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7078In this single-center, single-arm, open-label, phase II study, 57 patients with HER2-positive (as defined by 3+ IHC staining or evidence of amplification by FISH) salivary duct carcinoma were treated … (full text at CIViC) PMID 30452336 · Takahashi et al., 2019 · Open in CIViC | civic |
| Paclitaxel + TrastuzumabCombination | Malignant Salivary Gland NeoplasmALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID6170Case report of a 61-year-old caucasian male with a renal mass and subsequent liver metastases. Histopathological examination of the liver led to the diagnosis of metastastic adenocarcinoma of the sali… (full text at CIViC) PMID 23826550 · Firwana et al., 2012 · Open in CIViC | |
| CTNNB1 I35T + FBXW11 F517SFBXW11CTNNB11 | ||||||||
| (diagnostic) | Basal Cell AdenomaALIAS | Diagnostic | B | Supports Positive | 4 | submitted | EID12637A comprehensive molecular profiling (whole exome and whole transcriptome sequencing) determined that CTNNB1 I35T and FBXW11 F517S missense mutations were mutually exclusive and collectively account fo… (full text at CIViC) PMID 40389436 · Wong et al., 2025 · Open in CIViC | civic |
| FGFR2 S252W1 | ||||||||
| Erdafitinib | Salivary Gland Adenoid Cystic Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13161In the phase II NCI-MATCH EAY131-K2 trial, a patient with high-grade adenoid cystic carcinoma of the submandibular gland harboring an FGFR2 S252W (p.Ser252Trp) mutation achieved a partial response to … (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC | civic |
| IGF1R Overexpression1 | ||||||||
| Crizotinib + Gefitinib + LinsitinibCombination | Salivary Gland Adenoid Cystic Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID9024Within a preclinical study 15 patient samples with adenoid cystic carcinoma MYB-NFIB fusion activation loop can be modulated through AKT-dependent signaling induced by IGF1R overexpression and downreg… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Alectinib | Pancreatic Acinar Cell CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID10327Case report of a 62-year old male patient diagnosed with pancreatic acinar cell carcinoma. Liver metastases were diagnosed and treatment was started with gemcitabine plus nab-paclitaxel regimen. After… (full text at CIViC) PMID 35005993 · Gaule et al., 2022 · Open in CIViC | civic |
| NR4A3 rearrangement1 | ||||||||
| (diagnostic) | Acinar Cell CarcinomaALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12030In this study, using genome sequencing the authors identified a t(4;9)(q13;q31) in six acinic cell carcinoma cases (AciCCs). The 4q13 breakpoints were at the secretory Ca-binding phosphoprotein (SCPP… (full text at CIViC) PMID 30664630 · Haller et al., 2019 · Open in CIViC | civic |
| TP53 R213*1 | ||||||||
| (predisposing) | Salivary Gland Mucinous Adenocarcinoma | Predisposing | E | Supports Pathogenic | 3 | submitted | EID7321As seen in Figure 1, the R213* mutation is predominantly found in colorectal and breast cancers. The variant was described as being a frequent p53 nonsense mutation in melanoma, kidney chromophobe, es… (full text at CIViC) PMID 28249646 · Panaccione et al., 2017 · Open in CIViC | civic |
| MAML2 Fusion3 | ||||||||
| (diagnostic) | Salivary Gland Mucoepidermoid Carcinoma | Diagnostic | B | Supports Positive | 4 | accepted | EID11591In this 2010 study, the authors included 55 salivary gland mucoepidermoid carcinomas (MEC) and a control group of 36 potential MEC mimics, including Warthin tumors, oncocytomas, squamous cell carcinom… (full text at CIViC) PMID 20588178 · Seethala et al., 2010 · Open in CIViC | civic |
| 〃 | Salivary Gland Mucoepidermoid Carcinoma | Diagnostic | B | Supports Positive | 3 | accepted | EID11592In this 2013 study, the authors investigated 95 salivary gland mucoepidermoid carcinomas (MEC) using FFPE material. RT-PCR and FISH were utilized to detect CRTC1::MAML2 and CRTC3::MAML2 fusions, as we… (full text at CIViC) PMID 23035786 · Noda et al., 2013 · Open in CIViC | civic |
| 〃 | Salivary Gland Mucoepidermoid Carcinoma | Diagnostic | B | Supports | ||||
| NR4A3 Fusion4 | ||||||||
| (diagnostic) | Acinar Cell CarcinomaALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12816In this 2023 study, the authors evaluated the diagnostic utility of NR4A3 immunohistochemistry in acinic cell carcinoma (AciCC) of the salivary gland. The cohort included 128 AciCCs, comprising 85 cla… (full text at CIViC) PMID 36469101 · Klubíčková et al., 2023 · Open in CIViC | civic |
| 〃 | Acinar Cell CarcinomaALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12828In this 2019 study, the authors aimed to evaluate the usefulness of NR4A3 immunostaining and compare it with NR4A3 Fluorescence in situ hybridization (FISH) for the differential diagnosis of acinic ce… (full text at CIViC) PMID 31094928 · Haller et al., 2019 · Open in CIViC | civic |
| 〃 | Acinar Cell CarcinomaALIAS | |||||||
Data updated 19 minutes agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| civic |
| Capecitabine + Trastuzumab + Zoledronic AcidCombination | Malignant Salivary Gland NeoplasmALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6171Case report of a a 58 year old man with multiple bone metastases after local therapy of a carcinoma ex pleomorphic adenoma one year earlier. The original tumor tested strongly positive for HER2/neu by… (full text at CIViC) PMID 20504363 · Sharon et al., 2010 · Open in CIViC | civic |
| 3 |
| accepted |
EID11593In this 2009 study, the authors investigated 101 mucoepidermoid carcinomas (MECs) and 89 non-MEC salivary gland tumors using RT-PCR to detect CRTC1::MAML2, CRTC2::MAML2, and CRTC3::MAML2 fusions. The … (full text at CIViC) PMID 19749740 · Nakayama et al., 2009 · Open in CIViC |
| civic |
| Diagnostic |
| B |
| Supports Positive |
| 3 |
| accepted |
EID12336In this 2022 study the authors included 4 cases of sinonasal acinic cell carcinoma and 10 acinic cell carcinoma cases of the parotid gland. All four sinonasal patients were male, aged from 27 to 70 ye… (full text at CIViC) PMID 34873305 · Wang et al., 2022 · Open in CIViC |
| civic |
| 〃 | Acinar Cell CarcinomaALIAS | Diagnostic | C | Supports Positive | 3 | accepted | EID12337In this 2023 study the authors included 4 cases of acinic cell carcinoma of the salivary gland. The age of the patients ranged from 13 to 16 years, and included 2 males and 2 females. Immunohistochemi… (full text at CIViC) PMID 36169793 · Cole et al., 2023 · Open in CIViC | civic |